A 36 month observational study to describe the long-term efficacy and safety of ranibizumab 0.5 mg treatment in patients with visual impairment due to choroidalneovascularization (CNV) secondary to pathologic myopia (PM) First published 10/03/2015 Last updated 02/07/2024 EU PAS number:EUPAS8816 Study Finalised